GLYCATED ALBUMIN MARKET ANALYSIS
Increasing number of approvals of novel glycated albumin products in the market is expected to fuel the glycated albumin market growth in the near future
In 2015, Asahi Kasei Pharma Corporation received CE Marking for its new Lucica Glycated Albumin-L, an in vitro diagnostic assay kit, for glycated albumin (GA-L) in Europe. Lucica Glycated Albumin-L is used for the quantitative measurement of glycated albumin in human serum on compatible clinical chemistry analyzers. In 2015, Lucica Glycated Albumin-L received approval in Taiwan, in 2013 it received approval in Indonesia, and Korea.
In 2011, Diazyme Laboratories, Enzymatic glycated serum protein (GSP, Glycated Albumin) Assay Kit received approved by the U.S. Food and Drug Administration (FDA). Enzymatic glycated serum protein (GSP, Glycated Albumin) assay is two part liquid stable reagent, which can be used with various types of automated clinical chemistry analyzers. This product provides additional diagnostic values to clinical practices in diabetes management and screening. Thus, increasing approval of novel glycated albumin kits launched by key players in the market is expected to create a lucrative environment for the global glycated albumin market growth.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
